Boston Scientific Corporation (BSX): Price and Financial Metrics


Boston Scientific Corporation (BSX)

Today's Latest Price: $37.78 USD

0.28 (0.75%)

Updated Jun 2 1:21pm

Add BSX to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 132 in Medical - Devices & Equipment

See all "A" rated Strong Buy stocks

BSX Stock Summary

  • With a market capitalization of $52,475,629,575, Boston Scientific Corp has a greater market value than 96.5% of US stocks.
  • Price to trailing twelve month operating cash flow for BSX is currently 37.24, higher than 91.06% of US stocks with positive operating cash flow.
  • The volatility of Boston Scientific Corp's share price is greater than that of just 15.47% US stocks with at least 200 days of trading history.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Boston Scientific Corp are BAX, ATVI, EW, ABB, and ZTS.
  • Visit BSX's SEC page to see the company's official filings. To visit the company's web site, go to www.bostonscientific.com.
BSX Daily Price Range
BSX 52-Week Price Range

BSX Stock Price Chart More Charts


BSX Price/Volume Stats

Current price $37.78 52-week high $46.62
Prev. close $37.50 52-week low $24.10
Day low $37.48 Volume 4,187,840
Day high $37.93 Avg. volume 11,195,288
50-day MA $35.08 Dividend yield N/A
200-day MA $39.77 Market Cap 52.87B

Boston Scientific Corporation (BSX) Company Bio


Boston Scientific develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in three segments: Cardiovascular, Rhythm Management, and MedSurg. The company was founded in 1979 and is based in Marlborough, Massachusetts.

BSX Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target:Forecasted Gain:
$37.78$6.64-83%

We started the process of determining a valid price forecast for Boston Scientific Corp with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Boston Scientific Corp ranked in the 15th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. In terms of the factors that were most noteworthy in this DCF analysis for BSX, they are:

  • Boston Scientific Corp's effective tax rate, as measured by taxes paid relative to net income, is at 121 -- greater than 97.6% of US stocks with positive free cash flow.
  • The company's cost of debt, derived from its interest coverage, tax rate, and market capitalization, is greater than 60.79% of stocks in its sector (Healthcare).


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%-83%
1%-83%
2%-83%
3%-82%
4%-82%
5%-82%

Want more companies with a valuation profile/forecast similar to that of Boston Scientific Corp? See TECH, A, EW, QGEN, and TFX.


BSX Latest News Stream


Event/TimeNews Detail
Loading, please wait...

BSX Latest Social Stream


Loading social stream, please wait...

View Full BSX Social Stream

Latest BSX News From Around the Web

Below are the latest news stories about Boston Scientific Corp that investors may wish to consider to help them evaluate BSX as an investment opportunity.

Boston Scientific Launches DIRECTSENSE™ Technology

Boston Scientific (NYSE: BSX) announced the U.S. launch of the DIRECTSENSE™ Technology, a tool for monitoring the effect of radiofrequency (RF) energy delivery during cardiac ablation procedures. Available on the RHYTHMIA HDx™ Mapping System, the DIRECTSENSE Technology, which received U.S. Food and Drug Administration approval in April, is the only tool to monitor changes in local impedance – electrical resistance – around the tip of the INTELLANAV™ MiFi Open-Irrigated (OI) ablation catheter, offering physicians an additional measurement of therapy effect during an ablation.

Yahoo | June 1, 2020

How leaders should address race with their employees, the Warren Buffett of tech, and top healthcare startups

Hello, New York. Atlanta. Los Angeles. Denver. Dallas. Detroit. Washington, DC. Seattle. Miami. Chicago. Thousands marched in cities across the US last night, with many of the protests turning violent. The protests first broke out in Minneapolis after a black man, George Floyd, was killed after a white police officer knelt on his neck for nearly nine minutes during an arrest, and as Floyd said he couldn't breathe. The arrest was caught on video, and the Minneapolis police officer who knelt on George Floyd's neck has since been charged with third-degree murder and manslaughter . As Tati Bellamy Walker and Shana Lebowitz report, a memo from medical-device-manufacturing firm Boston Scientific on the killing of George Floyd is a case study in how leaders should address the events in Minneso...

Business Insider | May 31, 2020

How Has BSX Performed 30 Days Post Earnings

Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Investment Research | May 29, 2020

8 Stocks Viking Global Investors Continues to Buy

Visa and Cigna make the list Continue reading...

Yahoo | May 29, 2020

Boston Scientific Completes Approximately $2.0 Billion Aggregate Offerings of Common Stock and Mandatory Convertible Preferred Stock

MARLBOROUGH, Mass. , May 27, 2020 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) completed the concurrent offerings of (i) 29,382,500 shares of its common stock, which includes the exercise in full by the underwriters of their option to purchase up to 3,832,500 additional shares of common stock, at a public offering price of $34.25 per share and (ii) 10,062,500 shares of its 5.50% Mandatory Convertible Preferred Stock, Series A ("Mandatory Convertible Preferred Stock"), which includes the exercise in full by the underwriters of their overallotment option to purchase up to 1,312,500 additional shares of Mandatory Convertible Preferred Stock, at a price to the public and liquidation preference of $100.00 per share (collectively, the "offerings"). The net proceeds from the Comm...

Benzinga Feeds | May 27, 2020

Read More 'BSX' Stories Here

BSX Price Returns

1-mo 4.97%
3-mo -2.50%
6-mo -12.67%
1-year -1.33%
3-year 36.88%
5-year 110.94%
YTD -16.45%
2019 27.96%
2018 42.56%
2017 14.61%
2016 17.30%
2015 39.17%

Continue Researching BSX

Want to see what other sources are saying about Boston Scientific Corp's financials and stock price? Try the links below:

Boston Scientific Corp (BSX) Stock Price | Nasdaq
Boston Scientific Corp (BSX) Stock Quote, History and News - Yahoo Finance
Boston Scientific Corp (BSX) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8865 seconds.